OverviewSuggest Edit

Cullinan Oncology is a company that develops cancer treatments and a portfolio of oncology therapeutics. It offers business models for traditional drug development, portfolio management for distributing risk and streamlining the development of drugs. Cullinan Oncology caters to cancer hospitals, biopharmaceutical companies, and drug development organizations.
TypePublic
Founded2016
HQCambridge, MA, US
Websitecullinanoncology.com

Latest Updates

Employees (est.) (Dec 2020)20
Share Price (Jun 2021)$33.1(+12%)
Cybersecurity ratingBMore

Key People/Management at Cullinan Oncology

Owen Hughes

Owen Hughes

Chief Executive Officer, Director
Patrick Baeuerle

Patrick Baeuerle

Co-Founder, Acting Chief Scientific Officer, Biologics
Anthony Davis

Anthony Davis

Executive Director, Head of Quality Assurance
Bochong Li

Bochong Li

Director, Innovation
Juliet Labadorf

Juliet Labadorf

Associate Director, Corporate Finance
Raymond T. Keane

Raymond T. Keane

Chief Legal Officer
Show more

Cullinan Oncology Office Locations

Cullinan Oncology has an office in Cambridge
Cambridge, MA, US (HQ)
1 Main St
Show all (1)

Cullinan Oncology Financials and Metrics

Cullinan Oncology Revenue

USD

Net income (FY, 2019)

(21.7m)

EBIT (FY, 2019)

(22.3m)

Market capitalization (4-Jun-2021)

1.4b

Closing stock price (4-Jun-2021)

33.1

Cash (30-Sept-2020)

41.3m
Cullinan Oncology's current market capitalization is $1.4 b.
USDFY, 2018FY, 2019

General and administrative expense

5.0m5.5m

R&D expense

9.6m16.8m

Operating expense total

14.6m22.3m

EBIT

(14.6m)(22.3m)
Annual
USDFY, 2018FY, 2019

Cash

33.8m63.3m

Current Assets

34.2m100.1m

PP&E

233.0k182.0k

Total Assets

34.6m100.5m
Quarterly
USDQ3, 2020

Cash

41.3m

Current Assets

97.0m

PP&E

146.0k

Total Assets

97.3m
Annual
USDFY, 2018FY, 2019

Net Income

(14.2m)(21.7m)

Depreciation and Amortization

43.0k70.0k

Accounts Payable

225.0k639.0k

Cash From Operating Activities

(13.5m)(20.9m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(16.9m)30.4m

Depreciation and Amortization

53.0k47.0k

Accounts Payable

798.0k1.1m

Cash From Operating Activities

(16.0m)(20.3m)
USDFY, 2018

Financial Leverage

-1.7 x
Show all financial metrics

Cullinan Oncology Operating Metrics

Q3, 2020

Discovery Stage Products

4

IND-Enabling Stage Products

2

Phase I Trials Products

1
Show all operating metrics

Cullinan Oncology Acquisitions / Subsidiaries

Company NameDateDeal Size
Cullinan Amber Corp.
Cullinan Apollo Corp.
Cullinan Florentine Corp.
Cullinan Management, Inc.
Cullinan Mica Corp.
Cullinan Pearl Corp.

Cullinan Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Cullinan Oncology Online and Social Media Presence

Embed Graph

Cullinan Oncology News and Updates

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non…

Cullinan Oncology Announces Management Transition

CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, …

Cullinan Oncology Reports First Quarter 2021 Financial Results

Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florentine and Cullinan MICA

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hu…

Cullinan Oncology Blogs

Cullinan Oncology Completes $131.2 Million Series C Financing

Cullinan Oncology Completes $131.2 Million Series C Financing CAMBRIDGE, Mass., December 17, 2020 - Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, …

Jon Wigginton MD Receives SITC Visionary Legacy Award

Jon Wigginton MD Receives SITC Visionary Legacy Award CAMBRIDGE, Mass. – November 13, 2020 - Cullinan Oncology is proud to announce that its Chief Medical Officer, Jon Wigginton MD, has been honored by the Society for Immunotherapy of Cancer (SITC) as a recipient of its 2020 Visionary Legacy Award.…

Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer

Cullinan Oncology Appoints Jeff Trigilioas Chief Financial Officer CAMBRIDGE, Mass., October 29, 2020 - - Cullinan Oncology, LLC announced today the appointment of Jeffrey Trigilio as the company’s Chief Financial Officer. In addition to his primary financial responsibilities, Jeff will play an imp…

Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020

Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 CAMBRIDGE, Mass., September 17, 2020 – Cullinan Pearl, a Cullinan Oncology company, today announced that an abstract detailing the ongoing Phase 1/2a clin…

Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML

Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML CAMBRIDGE, Mass. and TŰBINGEN, Germany, September 14, 2020 – Cullinan Oncology, LLC, the German Cancer Researc…
Show more

Cullinan Oncology Frequently Asked Questions

  • When was Cullinan Oncology founded?

    Cullinan Oncology was founded in 2016.

  • Who are Cullinan Oncology key executives?

    Cullinan Oncology's key executives are Owen Hughes, Patrick Baeuerle and Anthony Davis.

  • How many employees does Cullinan Oncology have?

    Cullinan Oncology has 20 employees.

  • Who are Cullinan Oncology competitors?

    Competitors of Cullinan Oncology include ImmunoMet, Moleculin Biotech and 3sbio.

  • Where is Cullinan Oncology headquarters?

    Cullinan Oncology headquarters is located at 1 Main St, Cambridge.

  • Where are Cullinan Oncology offices?

    Cullinan Oncology has an office in Cambridge.

  • How many offices does Cullinan Oncology have?

    Cullinan Oncology has 1 office.